---
title: "Qyuns Therapeutics Launches Share Buyback as Board Deems Stock Undervalued"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/274983583.md"
description: "Qyuns Therapeutics Co., Ltd. has initiated a share buyback program after the board determined that the stock is undervalued. The company plans to repurchase approximately 2.49 million shares, about 1.10% of its issued capital, for around HK$50.75 million, to enhance shareholder value and market confidence. Future buybacks will depend on market conditions. The current analyst rating for the stock is a Hold with a price target of HK$22.00. Qyuns Therapeutics focuses on developing therapeutic products in the healthcare sector."
datetime: "2026-02-05T12:38:34.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/274983583.md)
  - [en](https://longbridge.com/en/news/274983583.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/274983583.md)
---

# Qyuns Therapeutics Launches Share Buyback as Board Deems Stock Undervalued

### Claim 50% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Qyuns Therapeutics Co., Ltd. Class H ( (HK:2509) ) just unveiled an update.

Qyuns Therapeutics has launched an on-market share repurchase program under a previously approved mandate, after its board concluded that the current share price significantly undervalues the company’s intrinsic worth and long‑term prospects. Between 6 November 2025 and 5 February 2026, the company repurchased approximately 2,487,800 shares, representing about 1.10% of its issued share capital, for a total consideration of roughly HK$50.75 million, with the shares to be held as treasury stock; the move is intended to bolster market confidence and enhance shareholder value, though future buybacks will remain subject to market conditions and board discretion, and the company has cautioned investors that there is no guarantee of further repurchases.

The most recent analyst rating on (HK:2509) stock is a Hold with a HK$22.00 price target. To see the full list of analyst forecasts on Qyuns Therapeutics Co., Ltd. Class H stock, see the HK:2509 Stock Forecast page.

**More about Qyuns Therapeutics Co., Ltd. Class H**

Qyuns Therapeutics Co., Ltd. is a biopharmaceutical company incorporated in the People’s Republic of China and listed in Hong Kong, focusing on the development and commercialization of therapeutic products. The company operates in the healthcare and life sciences sector and targets investors seeking exposure to innovative drug development and related medical technologies in the Chinese and broader Asian markets.

**Average Trading Volume:** 353,447

**Technical Sentiment Signal:** Buy

**Current Market Cap:** HK$4.65B

### Related Stocks

- [02509.HK](https://longbridge.com/en/quote/02509.HK.md)

## Related News & Research

- [ELFI offers new private student loan alternative for medical and healthcare students facing federal loan changes](https://longbridge.com/en/news/286929682.md)
- [UnitedHealth Group Incorporated $UNH Holdings Boosted by GSA Capital Partners LLP](https://longbridge.com/en/news/286878927.md)
- [Craneware Tightens Free Float with Latest Share Buyback Tranche](https://longbridge.com/en/news/286044879.md)
- [RBC Capital Sticks to Its Hold Rating for SCHOTT Pharma AG & Co. KGaA (1SXP)](https://longbridge.com/en/news/286214150.md)
- [08:57 ETHoratio Expands To Honduras Doubling Down on Nearshore Growth and Premium CX Delivery](https://longbridge.com/en/news/286569557.md)